Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001784850 | SCV002018852 | pathogenic | Mucopolysaccharidosis type 6 | 2021-10-29 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001784850 | SCV003934348 | likely pathogenic | Mucopolysaccharidosis type 6 | 2023-05-26 | criteria provided, single submitter | clinical testing | Variant summary: ARSB c.256_258delTAC (p.Tyr86del) results in an in-frame deletion that is predicted to remove 1 amino acid from the encoded protein. The variant was absent in 173184 control chromosomes (gnomAD). c.256_258delTAC has been reported in the literature in an individual affected with Mucopolysaccharidosis Type VI (Maroteaux-Lamy Syndrome) who was compound heterozygous with a (likely) pathogenic variant (Karageorgos_2004). This publication also reports experimental evidence evaluating an impact on protein function, showing that the variant construct results in very low ARSB activity when transfected into cells. The following publication has been ascertained in the context of this evaluation (PMID: 14974081). One clinical diagnostic laboratory has submitted a clinical-significance assessment for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified it as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |